CY1115376T1 - Βελτιωμενη μεθοδος - Google Patents
Βελτιωμενη μεθοδοςInfo
- Publication number
- CY1115376T1 CY1115376T1 CY20141100562T CY141100562T CY1115376T1 CY 1115376 T1 CY1115376 T1 CY 1115376T1 CY 20141100562 T CY20141100562 T CY 20141100562T CY 141100562 T CY141100562 T CY 141100562T CY 1115376 T1 CY1115376 T1 CY 1115376T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lenalidomide
- crystalline
- isoindol
- dione
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lighting Device Outwards From Vehicle And Optical Signal (AREA)
- Glass Compositions (AREA)
- Optical Communication System (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε βελτιωμένες μεθόδους για παρασκευή 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλ)-πιπεριδινο-2,6-διόνης (Ι) (λεναλιδομίδη) και ενδιαμέσου αυτής 3-(1-οξο-4-νιτρο-1,3-διυδρο-ισοϊνδολ-2-υλ)-πιπεριδινο-2,6-διόνης. Η παρούσα εφεύρεση περαιτέρω αφορά σε βελτιωμένες μεθόδους για παρασκευή κρυσταλλικής μορφής Α λεναλιδομίδης, χρήση της εν λόγω κρυσταλλικής μορφής Α ως δραστικό φαρμακευτικό συστατικό ή ως ενδιάμεσο στην παρασκευή περαιτέρω κρυσταλλικών ή άμορφων μορφών λεναλιδομίδης, συνθέσεις που περιλαμβάνουν κρυσταλλική μορφή Α λεναλιδομίδης και χρήση αυτών στην θεραπεία ασθένειας.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN383KO2009 | 2009-03-02 | ||
IN463KO2009 | 2009-03-16 | ||
EP10707950.1A EP2403845B1 (en) | 2009-03-02 | 2010-03-01 | Improved process |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115376T1 true CY1115376T1 (el) | 2017-01-04 |
Family
ID=54290149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100562T CY1115376T1 (el) | 2009-03-02 | 2014-07-24 | Βελτιωμενη μεθοδος |
Country Status (16)
Country | Link |
---|---|
US (1) | US8946265B2 (el) |
EP (1) | EP2403845B1 (el) |
JP (1) | JP5727944B2 (el) |
CN (1) | CN102414196A (el) |
AU (1) | AU2010220204B2 (el) |
CA (1) | CA2753241C (el) |
CY (1) | CY1115376T1 (el) |
DK (1) | DK2403845T3 (el) |
ES (1) | ES2487215T3 (el) |
HR (1) | HRP20140686T1 (el) |
NZ (1) | NZ595492A (el) |
PL (1) | PL2403845T3 (el) |
PT (1) | PT2403845E (el) |
SI (1) | SI2403845T1 (el) |
SM (1) | SMT201400100B (el) |
WO (1) | WO2010100476A2 (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
KR20130038232A (ko) | 2010-03-08 | 2013-04-17 | 낫코 파마 리미티드 | 무수 레날리도마이드 form-i |
KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
CA2842316A1 (en) * | 2011-07-19 | 2013-01-24 | Amplio Pharma, Llc | Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)piperidine-2,6-dione |
CN102838586A (zh) * | 2012-09-20 | 2012-12-26 | 重庆泰濠制药有限公司 | 一种制备来那度胺的方法 |
MX2015011905A (es) | 2013-03-13 | 2016-01-08 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. |
CA2901410C (en) | 2013-03-13 | 2023-09-12 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of traumatic injury |
ES2745041T3 (es) | 2013-03-13 | 2020-02-27 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios |
WO2014160686A1 (en) * | 2013-03-26 | 2014-10-02 | Celgene Corporation | Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof |
CN103601717A (zh) * | 2013-10-09 | 2014-02-26 | 湖南华腾制药有限公司 | 一种来那度胺的新型制备方法 |
LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
WO2014155371A2 (en) * | 2014-04-26 | 2014-10-02 | Shilpa Medicare Limited | Crystalline lenalidomide process |
US10392364B2 (en) | 2014-08-11 | 2019-08-27 | Avra Laboratories Pvt. Ltd. | Process for synthesis of lenalidomide |
WO2016026785A1 (en) * | 2014-08-19 | 2016-02-25 | Synthon B.V. | Process for making crystalline form a of lenalidomide |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
EA036205B1 (ru) * | 2015-12-22 | 2020-10-14 | Синтон Б.В. | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант |
US10899793B2 (en) | 2016-05-27 | 2021-01-26 | Regents Of The University Of Minnesota | Melanocortin ligands and methods of use thereof |
US11124541B2 (en) | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
EP3687987A4 (en) * | 2017-09-27 | 2021-03-24 | Biocon Limited | CRYSTALLINE FORMS OF LENALIDOMIDE |
WO2019138424A1 (en) * | 2018-01-11 | 2019-07-18 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
CN111196800B (zh) * | 2018-11-19 | 2022-10-11 | 欣凯医药化工中间体(上海)有限公司 | 一种制备来那度胺的方法 |
WO2022144924A1 (en) * | 2021-01-04 | 2022-07-07 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
KR20070057907A (ko) | 2004-09-03 | 2007-06-07 | 셀진 코포레이션 | 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법 |
WO2008128225A1 (en) | 2007-04-16 | 2008-10-23 | Momenta Pharmaceuticals, Inc. | Multi-dimensional chromatographic methods for separating n-glycans |
EP2220484A2 (en) | 2007-12-14 | 2010-08-25 | Generics [UK] Limited | Hplc method for analysing clopidogrel |
WO2009114601A2 (en) | 2008-03-11 | 2009-09-17 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
US20110263649A1 (en) | 2008-11-03 | 2011-10-27 | Generics [Uk] Limited | Crystalline form of lenalidomide and a process for its preparation |
WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
-
2010
- 2010-03-01 JP JP2011552515A patent/JP5727944B2/ja active Active
- 2010-03-01 WO PCT/GB2010/050352 patent/WO2010100476A2/en active Application Filing
- 2010-03-01 EP EP10707950.1A patent/EP2403845B1/en active Active
- 2010-03-01 SI SI201030679T patent/SI2403845T1/sl unknown
- 2010-03-01 CN CN2010800195527A patent/CN102414196A/zh active Pending
- 2010-03-01 US US13/254,249 patent/US8946265B2/en active Active
- 2010-03-01 NZ NZ595492A patent/NZ595492A/xx unknown
- 2010-03-01 CA CA2753241A patent/CA2753241C/en active Active
- 2010-03-01 AU AU2010220204A patent/AU2010220204B2/en active Active
- 2010-03-01 DK DK10707950.1T patent/DK2403845T3/da active
- 2010-03-01 PL PL10707950T patent/PL2403845T3/pl unknown
- 2010-03-01 PT PT107079501T patent/PT2403845E/pt unknown
- 2010-03-01 ES ES10707950.1T patent/ES2487215T3/es active Active
-
2014
- 2014-07-16 HR HRP20140686AT patent/HRP20140686T1/hr unknown
- 2014-07-24 CY CY20141100562T patent/CY1115376T1/el unknown
- 2014-07-28 SM SM201400100T patent/SMT201400100B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK2403845T3 (da) | 2014-08-04 |
EP2403845B1 (en) | 2014-04-30 |
PL2403845T3 (pl) | 2014-09-30 |
CA2753241A1 (en) | 2010-09-10 |
US8946265B2 (en) | 2015-02-03 |
ES2487215T3 (es) | 2014-08-20 |
SI2403845T1 (sl) | 2014-09-30 |
US20120071509A1 (en) | 2012-03-22 |
WO2010100476A2 (en) | 2010-09-10 |
JP2012519207A (ja) | 2012-08-23 |
EP2403845A2 (en) | 2012-01-11 |
SMT201400100B (it) | 2014-11-10 |
NZ595492A (en) | 2013-07-26 |
CA2753241C (en) | 2015-06-16 |
HRP20140686T1 (hr) | 2014-09-26 |
AU2010220204B2 (en) | 2015-10-08 |
CN102414196A (zh) | 2012-04-11 |
WO2010100476A3 (en) | 2011-06-16 |
PT2403845E (pt) | 2014-08-04 |
AU2010220204A1 (en) | 2011-10-20 |
JP5727944B2 (ja) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115376T1 (el) | Βελτιωμενη μεθοδος | |
CY1119474T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
CY1119974T1 (el) | Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης | |
CY1122330T1 (el) | Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης | |
CY1118416T1 (el) | Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα | |
EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
ATE486601T1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
CY1110190T1 (el) | Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38 | |
GEP20135863B (en) | Substituted piperidines as ccr3 antagonists | |
EA201170884A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов орексина | |
EA201200741A1 (ru) | Способ получения этексилата дабигатрана | |
CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
UA112281C2 (uk) | Стабільні інсектицидні композиції і способи їх отримання | |
TR201904785T4 (tr) | (S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU. | |
NO20076635L (no) | Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter | |
EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
EA201101009A1 (ru) | АНТАГОНИСТЫ C5aR | |
EA201290726A1 (ru) | Новые соли для получения фармацевтических композиций | |
EA201100517A1 (ru) | Способ получения дабигатрана и его промежуточные соединения | |
EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
WO2013012485A3 (en) | Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
CY1119687T1 (el) | Κρυσταλλικο αλας της (s)-(2-(6-χλωρο-7- μεθυλ-1η- βενζο [d]imiδazoλ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ)φαινυλ) μεθανονης ως ανταγωνιστης υποδοχεα ορεξινης |